BAM15 vs Survodutide
A side-by-side research comparison of BAM15 and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | Survodutide |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 402.28 Da | 4,500 Da (approximate) |
| Half-life | Short (hours in animal models) | 5-7 days |
| Bioavailability | Oral (animal studies) | High (SubQ) |
| Typical dose | Not established for humans | 0.6-6.0 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Oral (research) | Subcutaneous |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.